Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is not on a statin or other lipid-modifying therapy~* Low or moderate risk participant~* Male participants, and female participants not of reproductive potential~Exclusion Criteria:~* Female participant of reproductive potential~* Participant is pregnant, breastfeeding, or expecting to conceive during the study~* Participant has history of cancer within 5 years of study (except certain types of skin and cervical cancer)~* Participant is a user of recreational or illicit drugs or has a recent history of drug and/or alcohol abuse~* Participant has donated or received blood within 8 weeks of study start or intends to give/receive blood during the study~* Participant consumes more than 3 alcoholic drinks per day or more than 14 alcoholic drinks per week~* Participant is currently experiencing menopausal hot flashes~* Participant currently engages in vigorous exercise or an aggressive diet regimen~* Participant is at high risk for heart conditions~* Participant has Type 1 or Type 2 diabetes mellitus~* Participant has poorly controlled cardiac arrhythmias~* Participant has a history of stroke or other hemorrhage~* Participant has poorly controlled high blood pressure~* Participant has a thyroid condition or other endocrine/metabolic disease that would affect serum lipids~* Participant has a disease of the kidney or liver~* Participant has an ulcer within 3 months of screening~* Participant is Human Immunodeficiency Virus (HIV) positive~* Participant is taking cyclical hormonal contraceptives or non-continuous hormone replacement therapy~* Participant is taking or has taken an Organic Anion Transporter (OAT1/3) inhibitor/substrate within 3 days of screening~* Participant has taken an anti-obesity medication within 3 months of screening~* Participant is taking coumarins~* Participant is taking Non-steroidal Anti-inflammatory Drugs (NSAIDs) (acetaminophen and Cyclooxygenase-2 (COX-2) inhibitors are allowed)~* Participant is taking more than 100 mg aspirin per day~* Participant is being treated with oral, intravenous, or injected corticosteroids or anabolic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK1903
- 2 (Type: PLACEBO_COMPARATOR): Placebo to MK1903

Based on this trial design, predict the completion outcome and termination type (if applicable).